BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

被引：0
|
作者：
Hao, Xiaoyao
Li, Hongyan
Liu, Xiaodong F.
Liu, Jinyu
Dai, Wenwen
Pan, Ying
Hu, Hui-Han
Li, Jun
Xia, Shukai
Lyu, Qun
Davis, Hugh M.
Chen, Mingjiu
Peng, Zeyu
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3135
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
    Kotanides, Helen
    Li, Yiwen
    Malabunga, Maria
    Carpenito, Carmine
    Eastman, Scott W.
    Shen, Yang
    Wang, George
    Inigo, Ivan
    Surguladze, David
    Pennello, Anthony L.
    Persaud, Krishnadatt
    Hindi, Sagit
    Topper, Michael
    Chen, Xinlei
    Zhang, Yiwei
    Bulaon, Danielle K.
    Bailey, Tim
    Lao, Yanbin
    Han, Bing
    Torgerson, Stacy
    Chin, Darin
    Sonyi, Andreas
    Haidar, Jaafar N.
    Novosiadly, Ruslan D.
    Moxham, Christopher M.
    Plowman, Gregory D.
    Ludwig, Dale L.
    Kalos, Michael
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1300 - 1310
  • [32] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Hua-ying Li
    Yi-li Chen
    Xiang-nan Deng
    Huan-huan Li
    Jie Tan
    Guo-jian Liu
    Yu-juan Zheng
    Min Pei
    Kai-ting Peng
    Li-li Yue
    Xiao-jia Chen
    Yu Liu
    Yong-shan Zhao
    Chun-he Wang
    Acta Pharmacologica Sinica, 2023, 44 : 2322 - 2330
  • [33] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Li, Hua-ying
    Chen, Yi-li
    Deng, Xiang-nan
    Li, Huan-huan
    Tan, Jie
    Liu, Guo-jian
    Zheng, Yu-juan
    Pei, Min
    Peng, Kai-ting
    Yue, Li-li
    Chen, Xiao-jia
    Liu, Yu
    Zhao, Yong-shan
    Wang, Chun-he
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (11) : 2322 - 2330
  • [34] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Hendriks, Djoke
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Heskamp, Sandra
    Wierstra, Peter J.
    Bremer, Edwin
    Helfrich, Wijnand
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [35] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Wierstra, Peter J.
    Heskamp, Sandra
    Bremer, Edwin
    Helfrich, Wijnand
    CANCER RESEARCH, 2018, 78 (13)
  • [36] HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities
    Chu, Wendi
    Xu, Hui
    Wang, Yanfei
    Xie, Yongle
    Chen, Yi-Li
    Tan, Xiaorong
    Huang, Chenghao
    Wang, Guifeng
    Wang, Qi
    Luo, Wenxin
    Xia, Ningshao
    Geng, Meiyu
    Xie, Zuoquan
    Wang, Chunhe
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (04):
  • [37] Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Gallenne, Tristan
    Maussang-Detaille, David
    Kramer, Arjen
    Nieuwenhuizen, Nellie
    Clements, Carina
    van Zoest, Katinka
    Nijhuis, Roy
    Visser, Therese
    Den Blanken-Smit, Renate
    Bartelink, Willem
    Zondag-van der Zande, Vanessa
    Kaldenberg, Linda
    van Loo, Pieter-Fokko
    Roovers, Rob
    Doornbos, Robert
    Price, Leo
    Braam, Stefan
    van Driel, Setareh
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    CANCER RESEARCH, 2015, 75
  • [38] Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
    Yang, Rui
    He, Qing
    Zhou, Hui
    Gong, Cheng
    Wang, Xing
    Song, Xingpan
    Luo, Fang
    Lei, Yang
    Ni, Qian
    Wang, Zili
    Xu, Shasha
    Xue, Yan
    Zhang, Man
    Wen, Haimei
    Fang, Lijuan
    Zeng, Liang
    Yan, Yongxiang
    Shi, Jian
    Zhang, Jing
    Yi, Jizu
    Zhou, Pengfei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63
    de Goeij, Bart E. C. G.
    Vink, Tom
    ten Napel, Hendrik
    Breij, Esther C. W.
    Satijn, David
    Wubbolts, Richard
    Miao, David
    Parren, Paul W. H. I.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) : 2688 - 2697
  • [40] A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47
    Liu, Shumin
    Lyu, Weidong
    Yin, Shuqiang
    Lei, Yang
    Zhuo, Qiudong
    Zheng, Liling
    Sun, Bin
    Tan, Shuangyu
    Jiang, Lidong
    Zhang, Teng
    Gao, Bo
    Xu, Rui
    Huang, Dechang
    Li, Yong
    Wu, Zibin
    Wu, David
    Wen, Yvonne Yu
    CANCER RESEARCH, 2023, 83 (07)
12345